Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 9, 2011, Pages 1106-1114

  Armstrong, L ^a   Sharif, J A ^a   Galloway, P ^a   McGrogan, P ^a   Bishop, J ^a   Russell, R K ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 TIOGUANINE NUCLEOTIDE; AZATHIOPRINE; CYCLOSPORIN A; DRUG METABOLITE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLMERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BONE MARROW TOXICITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; EOSINOPHILIC COLITIS; FEMALE; GENE MUTATION; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

6-MERCAPTOPURINE; ADOLESCENT; AZATHIOPRINE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; RETROSPECTIVE STUDIES; THIONUCLEOTIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053982932     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04848.x     Document Type: Article

References (31)

1. Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F,. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009; 30: 126-37.
2. Prefontaine E, Macdonald JK, Sutherland LR,. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010; 6: CD000545.
3. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
4. Marathias VM, Sawicki MJ, Bolton PH,. 6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation. Nucleic Acids Res 1999; 27: 2860-7. (Pubitemid 29335705)
5. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13. (Pubitemid 30171620)
6. Kurzawski M, Dziewanowski K, Gawronska-Szklarz B, Domanski L, Drozdzik M,. The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients. Ther Drug Monit 2005; 27: 435-41. (Pubitemid 41098817)
7. Barabino A, Torrente F, Ventura A, Cucchiara S, Castro M, Barbera C,. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther 2002; 16: 1125-30. (Pubitemid 34680755)
8. Cuffari C, Hunt S, Bayless T,. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6. (Pubitemid 32378583)
9. Ooi CY, Bohane TD, Lee D, Naidoo D, Day AS,. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 941-7. (Pubitemid 46525340)
10. Wright S, Sanders DS, Lobo AJ, Lennard L,. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 1123-8. (Pubitemid 38961966)
11. Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B,. A 6-thioguanine nucleotide threshold level of 400 pmol/8 × 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008; 103: 3115-22.
12. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD,. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-53.
13. Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010; 50 (Suppl. 1): S1-13.
14. Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2010; 17: 1301-7.
15. Colonna T, Korelitz BI,. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994; 89: 362-6. (Pubitemid 24074394)
16. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9. (Pubitemid 34638866)
17. Thomas CW Jr, Lowry PW, Franklin CL, et al. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003; 9: 237-45.
18. Decaux G, Prospert F, Horsmans Y, Desager JP,. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000; 135: 256-62. (Pubitemid 30132348)
19. Dervieux T, Boulieu R,. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998; 44: 551-5. (Pubitemid 28141350)
20. Campbell S, Kingstone K, Ghosh S,. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine. Aliment Pharmacol Ther 2002; 16: 389-98. (Pubitemid 34214517)
21. Sandborn WJ,. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001; 48: 591-2. (Pubitemid 32378572)
22. Smith M, Marinaki A, Arenas M, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther 2009; 30: 375-84.
23. Ding L, Zhang FB, Liu H, et al. Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2011 [Epub ahead of print].
24. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 973-83.
25. de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ,. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 2003; 239: 69-72. (Pubitemid 38112918)
26. Gisbert JP, Gomollon F,. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008; 103: 1783-800.
27. Daperno M, Sostegni R, Canaparo R, et al. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. Aliment Pharmacol Ther 2009; 30: 843-53.
28. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70. (Pubitemid 32989203)
29. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
30. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW,. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 715-29.
31. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.